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There have been substantial advances in neonatal medical care over the past 2 decades
that have resulted in the increased survival of very low birth weight infants, survival that
in some centers extends to 22 weeks gestational age. Despite these advances, there
continues to be signiﬁcant morbidity associated with extreme preterm birth that includes
both short-term and long-term pulmonary and neurologic consequences. No single
therapy has proven to be effective in preventing or treating either developmental lung
and brain injuries in preterm infants or the hypoxic-ischemic injury that can be inﬂicted on
the full-term brain as a result of in utero or perinatal complications. Stem cell–based
therapies are emerging as a potential paradigm-shifting approach for such complex
diseases with multifactorial etiologies, but a great deal of work is still required to
understand the role of stem/progenitor cells in normal development and in the repair of
injured tissue. This review will summarize the biology of the various stem/progenitor cells,
their effects on tissue repair in experimental models of lung and brain injury, the recent
advances in our understanding of their mechanism of action, and the challenges that
remain to be addressed before their eventual application to clinical care.
& 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Scientiﬁc, medical, and technological advances in the ﬁeld of
perinatal–neonatal medicine have resulted in increased sur-
vival rates for extremely low birth weight, near-term, and
term infants treated in neonatal intensive care units. How-
ever, respiratory and neurologic impairments continue to
constitute the major adverse outcomes of neonatal intensive
care unit survivors, resulting in lifelong morbidities that
include bronchopulmonary dysplasia (BPD) and several forms
of brain injury. Based on a recent study from the National2
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Neonatal Research Network Centers reporting on the 20-year
trend in survival and outcomes of preterm infants, there have
been overall modest reductions in several morbidities; how-
ever, the rates of BPD have increased.1 Speciﬁcally, from 2009
to 2012, BPD rates increased for all gestational ages from 22
up to 27 weeks with an overall incidence rate of 45% in this
age group. BPD affects at least 10,000 preterm infants in the
United States each year.
The pathophysiologic features and underpinning of BPD
have evolved over the last 2 decades such that the BPD ofpen access article under the CC BY-NC-ND license
d States, Grants R01 HL055454 and R01 HL085446 and United
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characterized by reduced numbers of alveoli and fewer blood
vessels but with less prominent ﬁbrosis and airway lesions
than the “old” BPD originally described by Northway et al.2
Nonetheless, BPD outcomes remain associated with signiﬁ-
cant long-term pulmonary morbidities, including airway
hyperreactivity, abnormal pulmonary function test results,
and, in some cases, emphysematous changes that persist
into adulthood. Moreover, secondary pulmonary hyperten-
sion has been reported in moderate to severe cases of BPD
and is associated with increased mortality.3,4 All in all, BPD is
not just a disease of the neonatal period or even of early
childhood, but rather a condition that carries lifelong con-
sequences including the development of chronic obstructive
pulmonary disease of adulthood. Speciﬁc therapies for BPD
are lacking, and this disease persists despite gentler ventila-
tion strategies and improvements in neonatal intensive care.
Further, newly adopted drugs or tested therapies such as
inhaled nitric oxide, antioxidants, vitamin A, caffeine, and
others have either failed or have minimal effect on BPD
outcomes. Steroids can decrease BPD but may be linked to
long-term adverse neurologic outcomes or potentially asso-
ciated with increased death rate as reported recently by the
Neonatal European Study of Inhaled Steroids Trial Group.5
Thus, the search for better treatment strategies to prevent
and treat BPD continues.
Periventricular leukomalacia (PVL) is a consequence of the
same perinatal insults of inﬂammation and oxidative damage
on a developing brain that form the underpinnings of BPD.
The new PVL, like the new BPD, is different, presenting with
more diffuse damage in the central cerebral white matter
with secondary decreases in cortical gray matter volume but
without cystic changes more typical of the focal necrosis
deep inside the periventricular white matter of the classic
cystic PVL. In addition to the preterm brain, the full-term
brain is susceptible to hypoxic-ischemic injury as a conse-
quence of inadequate blood ﬂow and oxygen delivery.
Hypoxic-ischemic encephalopathy (HIE) occurs in 1–3 term
births per 10006 and can result from acute blood loss secon-
dary to placental abruption, fetal maternal hemorrhage, or
prolapsed umbilical cord, among other insults. Although
therapeutic hypothermia has become standard therapy for
HIE, there are still a large number of infants who die or go on
to develop severe neurologic impairments and cerebral
palsy.7 We are in urgent need of additional new treatments
for this devastating disease, as well as new strategies to treat
PVL, BPD, and other related complications of preterm birth
that adversely affect the long-term normal development of
these children.
Evidence of stem cell depletion in PVL and BPD
The preterm infant is exposed to several risk factors that
result in tissue damage of multiple organs through common
mechanisms that include inﬂammation, infection, and ische-
mia/reperfusion, all promoting the production of free oxygen
radicals. In addition, the premature deprivation of protective
and nutritive factors provided by the placenta and the
maternal circulation plays a key role in exacerbating the
injury. The common pathway of such insults leads to alteredprogramming of development that is characterized by arrest
in normal organ growth with tissue simpliﬁcation. Emerging
evidence suggests that loss of endogenous stem/progenitor
cells required for normal cell differentiation and tissue repair
may underlie the pathobiology of such injury.
Stem cells are primitive cells that can undergo self-renewal
and have the potential to differentiate into multiple cell
types. They are critical for normal development and also for
the maintenance of normal physiology by contributing to
organ repair and regeneration throughout life. Depletion or
dysfunction of endogenous stem cells underlies disease
development and aging. The complex architecture of the
lung is maintained by the presence of rare populations of
multipotent endogenous stem cells that are regulated by
speciﬁc environmental signals. Their speciﬁc identiﬁcation,
characterization, and role in normal development and repair
are being actively investigated. Further, stem cells from the
bone marrow, the peripheral blood, or other tissue sources
are also thought to participate in organ repair by their
recruitment to sites of injury. Experimental and clinical
studies support the notion that loss of circulating and tissue
progenitor cells could be a mechanism underlying the abnor-
mal developmental growth pattern in diseases such as BPD.
For example, some reports have linked BPD risk with
decreased endothelial progenitors in the circulation as
assessed through clonogenic analysis of late outgrowth
endothelial colony-forming cells (ECFCs).8,9 In addition,
lung-resident mesenchymal stem cells (MSCs) isolated from
the tracheal aspirates of preterm neonates display an altered,
proinﬂammatory phenotype,10,11 suggesting that both deple-
tion and dysfunction of endogenous progenitor stem cells
may predispose to the development of BPD.
As in the developing lung, the developing brain is com-
posed of progenitor cells that are critical for normal growth
and repair. Premyelinating oligodendrocytes (preoligodendro-
cytes) are progenitor cells that are present in great abundance
in the preterm brain and progressively differentiate to mature
oligodendrocytes between 28 and 40 weeks gestational age to
form the myelin sheath. Preoligodendrocytes, but not mature
oligodendrocytes, are highly vulnerable to inﬂammation and
oxidative stress and are preferentially lost in response to
perinatal insults.12 Loss of preoligodendrocytes results in
hypomyelination of the central cerebral white matter and
associated complications of gray matter loss that form the
hallmark of diffuse PVL.
Altogether, accumulating evidence suggests an important
role for progenitor stem cells in both supporting and main-
taining normal organ growth in development and disease.
Endogenous progenitor cells have been isolated from several
sources and are increasingly being tested in experimental
models of disease and in the case of MSCs, in several human
trials including BPD. This review will summarize current
knowledge on the different types of progenitor stem cells
with a particular focus on the biology of MSCs and their
protective role in experimental models of brain and lung
injury, as well as their clinical application to date. Further, we
shall summarize emerging evidence on their mechanisms of
action that includes the shedding of exosomes, extracellular
vesicles that carry and transmit key mediators of the MSC
biologic effect.
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Mesenchymal stromal (stem) cells have been extensively
studied in preclinical models of disease and in human trans-
plantation studies. They have the ability to self-renew, and
their progeny has the ability to differentiate into a variety of
cell lineages. They were originally described as a ﬁbroblast-
like population in bone marrow, and, as the ﬁeld evolved,
they were denoted as bone marrow mesenchymal stem cells
or multipotent mesenchymal stromal cells. MSCs have sub-
sequently been detected and isolated from a variety of
tissues, including adipose tissue, umbilical cord blood, Whar-
ton’s jelly, placenta, and even adult lung tissue.13–17 Minimal
criteria were published in 2006 by the Mesenchymal & Tissue
Stem Cell Committee of the International Society for Cellular
Therapy, mainly based on the presence or absence of cell
surface markers, adherence to plastic, and differentiation
potential.18 Progress in the ﬁeld since then, and better under-
standing of the biology and functional attributes of MSCs,
have generated a call for invigoration of the criteria and
deﬁnition of MSCs in order to establish a more relevant
framework for their study and their potential therapeutic
uses.19
MSCs of bone marrow origin were ﬁrst proven to have
efﬁcacy in models of acute and ﬁbrotic lung injury. Thera-
peutic properties were subsequently demonstrated in various
disease models with MSCs isolated from other tissues,
including the human adult lung and human embryonic stem
cells (hESC) stimulated to differentiate into MSCs.20,21 In
general, MSCs are easy to isolate in large numbers from
different sources. Adipose-derived MSCs, for instance, are
available in large quantities from liposuction procedures, and
are thus considered major candidates for future approaches
to regenerative medicine.22 Wharton’s jelly MSCs are easy to
isolate from the umbilical cord, a tissue normally discarded at
birth, and, importantly, they have the potential to be used in
an autologous fashion.
Unlike ES cells, MSCs can be easily expanded in vitro under
standard culture conditions while maintaining their undiffer-
entiated state and continuing to express MSC markers for
several passages. In addition, they do not carry the terato-
genic potential of ES cells after in vivo transplantation.23
MSCs are also thought to be immunoprivileged in that they
evade clearance by the recipient immune system24 due to low
expression of the major histocompatibility complexes and
their ability to inhibit proliferation and function of immune
cells, such as dendritic cells, NK cells, and T and B lympho-
cytes.25–27 MSCs can also be genetically engineered without
losing their stem cell properties and their differentiation
potential.
However, the role of MSCs in the ﬁeld of regenerative
medicine is not well deﬁned and requires further study.
Despite their ease of isolation and the existence of pheno-
typic markers for MSCs, no correlation between their pheno-
typic characteristics and immunomodulatory activity or lung
regeneration capacity has been established. This is further
complicated by the many sources of MSCs, the different
culture techniques, as well as by species-speciﬁc properties.
Although MSCs isolated from different sources express
widely accepted markers, adhere to plastic, and showbaseline differentiation potential to osteoblast, chondroblast,
and adipocyte lineage in vitro, there remains a large variation
in differentiation capacity and gene transcription programs
depending on the tissue source and species of these cells.28–30
Even if MSCs maintain their differentiation potential and
differentiation markers after genetic manipulation or expan-
sion in culture, these properties do not ensure immunomo-
dulatory and regenerative capacity. Moreover, bone marrow–
derived MSCs are the best characterized and have been
shown to have cytoprotective effects; yet, they have also
been reported to accumulate genetic mutations after exten-
sive expansion.31–33 This genomic instability may account for
the unusual in vitro behavior, with early cultures growing
rapidly, but eventually giving rise to heterogeneous popula-
tions with variable properties that are often unable to
reproduce the protective MSC effect.
Currently, our knowledge remains incomplete on the sig-
nals required to maintain the therapeutic/regenerative MSC
phenotype upon expansion in vitro. In addition, because
there is no one speciﬁc marker of MSC phenotype, we need
greater insight into the cellular markers that deﬁne this
phenotype, and the ISCT marker panel may not be sufﬁcient
in all cases. Further work is necessary to resolve the above
ambiguities and develop rigorous standards to ensure repro-
ducibility in preclinical studies. This hurdle is compounded
by the fact that preclinical models of lung disease have
diverse precipitating triggers, some more and some less
relevant to human disease. Although lung inﬂammation is
the most common denominator in these models, the choice
of the particular model may be as important to a successful
future translation to the clinic as the MSC phenotype used to
treat the animals.
Mesenchymal stem cells in BPD—Preclinical studies
Stem cell therapies have been extensively tested in preclin-
ical models of BPD with encouraging results. Given the
complex architecture of the lung, different cell therapy
approaches have been implemented, including the use of
3D bioengineered and decellularized scaffolds populated with
progenitor cells. To date, preclinical studies of BPD have
focused on stem cells harvested from sources such as bone
marrow, blood, umbilical cord, and adipose tissue and tested
in the hyperoxia-induced neonatal murine and rat models,
with results that show suppression of inﬂammation,
improved survival, and marked attenuation in alveolar and
lung vascular injury and the associated pulmonary hyper-
tension.34–36 Administration of bone marrow MSCs on post-
natal day 4 prevented the BPD changes in lung architecture
and vascular remodeling evident at 14 days of hyperoxia in
the control animals in both mouse34 and rat models.36
Interestingly, the cell-free MSC-conditioned media (CM)
afforded better protection than the cells in preserving the
lung architecture and preventing alveolar loss in the Aslam et
al.34 study. These experiments have been reproduced by
several other groups using rodent bone marrow MSCs or
MSCs derived from human cord blood and their cell-free
CM.37–40 In this neonatal hyperoxia model, human umbilical
cord blood (UCB)–derived MSCs delivered intratracheally (IT)
were shown to confer signiﬁcant protection only if they were
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niﬁcantly, there were no synergies with combined early plus
late MSC transplantation.41 Importantly, a single dose of bone
marrow cell-free MSC-CM administered IV after 14 days of
hyperoxia, when disease had already developed inhibited
lung inﬂammation, reversed pulmonary hypertension and
the pruning of the distal vascular tree, and markedly amelio-
rated lung ﬁbrosis, collagen deposition, and alveolar destruc-
tion, although the lungs manifested some degree of residual
emphysema compared with normoxic controls.42
The active moieties that confer the therapeutic efﬁcacy of
MSCs remain elusive but likely include secreted proteins,
nucleic acids, and membrane components, with, as discussed
below, some potentially packaged in microvesicles released
by MSCs. Use of the MSC secretome can represent an exciting
and promising new approach to therapeutic interventions for
certain lung diseases because it bypasses concerns associated
with live cell treatments. Nevertheless, this is still a budding
ﬁeld; a recent paradigm that argues for the need to use live
MSCs rather than merely their products demonstrates that
mitochondrial transfer from MSCs to resident cells confers
protection against lung injury.43 Beyond treating BPD pathol-
ogy, administration of bone marrow–derived MSCs (BM-
MSCs) or their secretome has been shown to be effective in
ameliorating injury and/or reestablishing homeostasis in
several preclinical models of lung disease, including pulmo-
nary hypertension, acute lung injury, pulmonary ﬁbrosis, and
asthma, among others.44–52
Combined, the above studies support a protective role for
bone marrow–derived MSCs as well as human cord blood
MSCs or the MSC secretome in preventing or reversing injury
in the neonatal rodent hyperoxic models of BPD. Long-term
follow-up of MSC-treated animals revealed a protective effect
that is sustained at 100 days after a single dose of MSCs or
their CM, both delivered IT, with cells having a better long-
lasting effect than the media.37 A 6-month follow-up evalua-
tion after a single dose of IT MSCs or multiple intraperitoneal
(IP) injections of MSC-CM for 17 days after hyperoxia in the
neonatal rat resulted in improved exercise capacity and lung
histology compared to untreated controls.40 The successful
methods of delivery reported thus far include IV, IT, or IP, and
all have shown therapeutic effects. The best route remains to
be determined but a recent study suggested that IT admin-
istration of MSCs was more efﬁcacious that IV using the
neonatal rat hyperoxia model.53 In contrast, IV MSC injection
halted lung deterioration, whereas IT MSCs had no effect on
lung histology or dysfunction in an adult mouse model of
elastase-induced emphysema,54 pointing to potentially
disease-speciﬁc and age-speciﬁc differential responses to
the most optimal route for MSC delivery.
Other stem cell therapies in preclinical models of BPD
The lung developmental reprogramming that underlies BPD
is characterized by simpliﬁcation of both the airway compo-
nents as well as the vascular tree, with angiogenesis likely
being the driver for both normal lung vascular and alveolar
growth.55,56 To speciﬁcally target the vascular aspects of lung
growth, many investigators have examined vascular progen-
itor cells as potential treatment strategies for experimentalBPD. In the past decade, endothelial progenitor cells (EPCs)
have been investigated as biomarkers as well as cell therapy
to promote angiogenesis and vascular repair in vivo. Asahara
et al. revolutionized the ﬁeld in 1997 with the identiﬁcation of
circulating EPCs in the peripheral blood that could differ-
entiate into mature endothelial cells and be incorporated in
the vessels of animal models of disease.57 Several subsequent
studies showed the existence of more than one EPC pheno-
type, each with distinct growth and angiogenic character-
istics. The isolated cells that form colonies within 5 days in
culture (early outgrowth EPCs) exhibit macrophage-like phag-
ocytic activity and promote angiogenesis but do not incorpo-
rate into blood vessels in vivo. The second population of
putative EPCs isolated from peripheral blood is highly pro-
liferative and generates colonies within 14–21 days (late
outgrowth EPCs).58,59 It is these endothelial colony-forming
cells (ECFCs) rather than the early outgrowth, hematopoietic-
like angiogenic progenitors that are able to incorporate
in vivo and form chimeric vessels. Both early EPCs and ECFCs
have been used as therapeutic agents in several preclinical
models of systemic vascular disease as well as in models of
BPD. Administration of bone marrow–derived angiogenic
EPCs from healthy mice rescued the alveolar and vascular
injury in hyperoxic mice.60 In a neonatal bleomycin model of
lung injury, ECFCs and ECFC-CM prevented pulmonary hyper-
tension, but neither had an ameliorative effect on the
architectural alveolar injury of this model.61 Intravenous
delivery of human umbilical cord blood–derived ECFCs to
immunocompromised mice prevented alveolar injury and
pulmonary hypertension from hyperoxia exposure, both
features of severe BPD.62 As was the case with MSCs, there
was minimal engraftment of ECFCs in the recipient lungs,
and the reparative ECFC effect was recapitulated with the
daily administration of cell-free media. The improvements in
lung structure and function persisted for at least 10 months
post-ECFC therapy in this model.
Cells isolated from the human amniotic epithelium (AECs)
have also been explored in preclinical models of BPD. These
cells are not well characterized and likely constitute a mixed
population with distinct regenerative and anti-inﬂammatory
potential similar to MSCs. They have low immunogenic
potential and are considered “stem-like” as they are able to
differentiate into mesodermal, ectodermal, and endodermal
lineages in vitro.63 These cells were initially shown to have
antiﬁbrotic and anti-inﬂammatory effects in mice treated
with bleomycin.64 Subsequently, using the fetal lamb model,
intra-amniotic LPS-induced lung injury was not reduced with
IV administration of AECs although there was signiﬁcant
reduction in inﬂammation.65 In a study using in utero
ventilation of fetal sheep to induce BPD, IV plus IT admin-
istration of AECs successfully ameliorated lung structure with
rare engraftment and transdifferentiation events pointing to
paracrine mechanisms of protection.66
For recent reviews on cell-based therapies for the injured
lung see Refs. 19 and 67–72.
Lung-resident MSCs
Preclinical studies in lung injury models have predominantly
investigated the effects of administration of exogenous stem
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bors endogenous stem and progenitor cells that are rapidly
mobilized upon cellular injury, proliferating and differentiat-
ing to repair and regenerate injured tissue. Among the
epithelial progenitor cells that have been characterized in
the mouse respiratory system are the basal cells of the
proximal tracheobronchial region and submucosal glands,
the secretory cells in the conducting airways, as well as those
of the bronchoalveolar duct junction. Such tissue-resident
progenitor cells are important regulators of pulmonary
homeostasis and have crucial involvement in processes such
as inﬂammation, angiogenesis, and ﬁbrosis. Although the
lung-resident MSCs represent a multipotent precursor
population with reparative and regenerative functions,
they may react in opposing ways to different environmental
cues, and, under certain circumstances, actually participate
in the pathology of disease (for recent reviews see Refs. 70
and 73).
In a bleomycin-induced model of pulmonary ﬁbrosis, the
pathology was associated with the loss of endogenous lung-
resident MSCs and transplantation of lung-resident MSCs,
isolated as the “side population” from naïve animals, amelio-
rated disease, and restored effector T-cell responses.74 Con-
versely, using a mouse model of targeted deletion of
extracellular superoxide dismutase, Chow et al.75 reported
that the increased oxidative stress generated dysfunctionality
in the resident lung MSCs, causing them to contribute to
pulmonary microvascular remodeling. Hyperoxic injury
increases the activity of the beta-catenin pathway in a mouse
model of BPD, and this pathway activation was also reported
in lung-resident MSCs isolated from tracheal aspirates of
premature infants with respiratory distress. Because activa-
tion of the beta-catenin pathway leads to myoﬁbroblastic
differentiation, the authors advance the premise that the
increased numbers of dysfunctional lung-resident MSCs
present in BPD patients may contribute to the pathology
of this disease.76 The proposition that exogenous, nonlung
MSCs exert their therapeutic effect by facilitating the mobi-
lization of the lung-resident progenitor cells, or by protect-
ing them from injury, was investigated in the hyperoxia-
induced murine model of BPD.77 The lungs of neonatal mice
exposed to hyperoxia and treated with BM-MSCs or media
conditioned by BM-MSCs had a signiﬁcantly higher number
of bronchoalveolar stem cells (BASCs), an adult lung stem
cell population capable of self-renewal and differentiation
in vitro, and shown to proliferate in response to bronchiolar
and alveolar lung injury in vivo. This is an intriguing
observation that needs to be further investigated and
validated.
The recurrent theme in the above studies appears to be that
the therapeutic action of exogenous MSC treatment on lung
injury is predominantly an immunomodulatory paracrine
function. The primary observation is the suppression of
inﬂammatory responses, and in the models tested, media
conditioned by MSCs appear to be as efﬁcacious as or even
more efﬁcacious than cell transplantation. On the other hand,
based on the current literature, the role of lung-resident MSCs
in repairing injured tissue or contributing to the injury itself
remains unresolved.Mesenchymal stem cells in brain injury—Preclinical
Stem cell treatments for neonatal brain injury have used
neural stem cells, embryonic stem cells, bone marrow–
derived MSCs, umbilical cord blood (UCB) stem cells, and iPS
cells. Such treatments have been effective for the most part
in conferring signiﬁcant neuroprotection, neuroregeneration,
and improvement of functional outcomes in animal models
of neonatal hypoxia-ischemia, cerebral palsy, and stroke (for
recent reviews see Refs. 71 and 78–85). For the purposes of
this review, we will focus on the use of BM-MSCs and UCB-
MSCs. The demonstration of efﬁcacy of human UCB-MSCs in
these models was an especially promising development,
since hematologic malignancies and immunodeﬁciencies
are routinely treated with UCB transplantation. This led to
the initiation of a number of clinical trials to study the role of
autologous or allogeneic UCB transplantation in traumatic
brain injury in children (http://clinicaltrials.gov).
As in the case of the models of MSC treatment for lung
diseases, a consensus has been formed that donor MSCs do
not survive long-term in the recipient brain, and they do not
engraft or differentiate to replace damaged tissue directly but
rather home to the injured tissue and respond to signals of
local injury by secreting trophic and immunomodulatory
moieties. The paracrine action of MSCs facilitates the repair
process made by the parenchymal cells of the recipient, and
such processes may include blood vessel regeneration,
replacement of damaged nerve cells, and improved survival
of intrinsic neuronal cells. The repair process is facilitated by
a signiﬁcant dampening of inﬂammatory pathways. Indeed,
on the basis of in vitro studies, it has been suggested that the
therapeutic function of MSCs resides in their ability to repro-
gram brain microglia into a unique M2-like polarization state
characterized by increased phagocytic activity and upregu-
lated expression of anti-inﬂammatory mediators (Fig.). It has
been suggested that this phenotypic switch contributes to the
resolution of inﬂammation and tissue repair.86 Just as in the
lung, there are also suggestions that the donor MSC secre-
tome may actually activate the endogenous tissue-resident
stem cells and enhance their function, although as in the
lung, more studies are necessary to ﬁrmly establish this
crucial concept.
Methods of delivery of donor MSCs to the injured brain
include intraventricular injections, intravenous injections,
and intranasal administration. The more complicated and
direct intraventricular route is generally effective; for exam-
ple, in a model of neonatal stroke with severe brain injury
induced by middle cerebral artery occlusion, human UCB-
MSCs transplanted into newborn rats 6 h after the injury
signiﬁcantly improved the injury-associated abnormalities,
including brain infarct volume, impaired functional tests, and
histopathology (assessed up to 28 days postinjury).87 Simi-
larly, in the rat model of periventricular white matter injury
induced by intracerebral injections of ibotenic acid at post-
natal day 5, transplantation of labeled neonatal rat MSCs
resulted in signiﬁcantly increased antimyelin immunoreac-
tivity in the corpus callosum and improved reaching and
retrieval skills.88 Intracardial injection has been used to
deliver human BM-MSCs in a rat model of HIE with moderate
Fig – A schematic on the parallel actions of MSC treatment on injured lung or brain. Tissue injury precipitates an
inﬂammatory response by activating microglia and lung macrophages to a proinﬂammatory state (red icons). MSC
transplantation restores homeostasis mainly though paracrine actions. Among such actions are the repression or reversal of
the proinﬂammatory state, resulting in a shift in the balance toward an anti-inﬂammatory state (green icons). In the anti-
inﬂammatory state, endogenous resident stem cells can repair tissue more efﬁciently. A possible parallel mechanism, as
preliminary reports suggest, could be that MSC factors act directly on endogenous stem cells, mobilizing them to proliferate
and differentiate. Extracellular vesicles, including exosomes, are key functional vectors within the MSC secretome as the
therapeutic effects of MSC treatment can be efﬁciently recapitulated by cell-free, exosome-based treatments. (A) Biogenesis of
exosomes in MSC multivesicular bodies (MVB) and release upon fusion of the MVB with the plasma membrane. (B) Uptake of
MSC exosomes by a lung macrophage, and release of the exosomal cargo (X) into the recipient cell. N: nucleus. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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volume and moderate improvement in function.89 Studies in
the same mouse model compared the IV route to the IP route
in delivering MSCs to the brain and, perhaps not surprisingly,
found the former superior.90 The most efﬁcient method of
delivering MSCs to the injured brain appears to be the intra-
nasal route. The long-term safety of intranasal administra-
tion of MSCs (0.5 million cells per animal), in the mouse
model of HIE, was assessed by examining the recipient
animals 14 months postinjection. Histopathological analysis
of multiple organs per animal revealed no signiﬁcant increase
in systemic pathological lesions or neoplasia in the nasal
turbinates, brain, or other organs examined. The treated
animals exhibited signiﬁcant improvement of sensorimotor
and cognitive functions compared with the group receiving
the vehicle, and this improvement resulting from the MSC
treatment was, in the authors’ assessment, lifelong.91
In the mouse model of neonatal HIE, mouse BM-MSC
transplantation directly into the brain or through the intra-
nasal route can improve functional outcomes, reduce lesion
volume, increase differentiation of recently divided cells
toward neurons and oligodendrocytes and decrease prolifer-
ating inﬂammatory cells and can also signiﬁcantly reduce the
contralesional axonal remodeling induced by hypoxic-
ischemic (HI) brain injury.92–94 A single dose was sufﬁcientfor a marked and long-lasting beneﬁcial effect, and a mini-
mum effective dosage of 0.5 million MSCs per animal was
determined. The donor cells were observed to reach the
lesion site 24 h postinjection, and treatment at 10 days
post-HI was effective, but not at 17 days post-HI, indicating
that an optimal therapeutic window exists.95 Interestingly,
the nature of protection depended on the time of delivery of
MSCs to the injured brain. A single injection either at day 3 or
day 10 postinsult increased neurogenesis, but in the case of
two injections, one at day 3 and the second at day 10, the
second MSC application did not increase neurogenesis but
promoted corticospinal tract remodeling. This observation
has led to the interesting suggestion that the function of
MSCs is dictated by adaptive speciﬁc signals provided by the
damaged and regenerating brain.96,97
In this model, it has been well established that the
therapeutic action of the transplants is through secretion of
trophic factors and stimulation of the endogenous repair
processes.92,93 Similarly, in the rat model of periventricular
white matter injury, labeled donor rat BM-MSCs were
observed to migrate from the injection site to the lesion
area, but little evidence of differentiation of donor cells into
neuronal phenotypes was found, indicating an indirect,
probably paracrine mechanism for the MSC neuroprotective
effect.88 That this mechanism may involve enhancement of
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gested by in vitro studies where human BM-MSCs were
shown to induce mouse neural stem cells to differentiate
into neurons, leading the authors to suggest that this prop-
erty represents a reﬂection of the neuroregenerative potential
observed in vivo.98
Genetically modifying MSCs to overexpress protective mol-
ecules, such as trophic factors, can make them more efﬁca-
cious, as shown by MSCs overexpressing and secreting brain-
derived neurotrophic factor (BDNF). Such modiﬁed cells were
shown to regulate proliferation and differentiation of neural
stem cells in vitro and in the mouse model of HIE and
improve outcomes in vivo when compared with control (not
BDNF-overexpressing) MSCs. This improvement was only
partially or not at all recapitulated if other growth factors
were overexpressed, instead of BDNF.99 Interestingly, in the
rat model of neonatal stroke induced by transient middle
cerebral artery occlusion, intranasal delivery of MSCs was
efﬁcacious in ameliorating white matter loss and improving
function tests, but overexpression of BDNF by donor MSCs
did not confer any additional long-lasting beneﬁt,100 high-
lighting the restrictive range of the genetically modiﬁed
MSCs. A combination of hypothermia, the only clinically
available treatment currently for HIE, with human UBC-
MSC transplantation was assessed, and it was shown that
the combination improves outcomes in the neonatal rat
model of carotid artery ligation plus hypoxia. Although
intraventricular MSC transplantation (0.1 million cells per
animal) was more efﬁcacious than hypothermia (target
temperature at 321) at improving certain outcomes, a
greater improvement in brain infarction volume, histopa-
thology, cerebrospinal ﬂuid cytokine levels, and function in
behavioral tests was observed when the two therapies were
combined.101
Cell-free therapies—Exosomes
In the ﬁeld of MSC research, once the consensus started to
form that donor cells do not engraft long-term or differentiate
in signiﬁcant numbers in the injured recipient tissue, inves-
tigators, including our group, started to explore paracrine
mechanisms to explain the robust cytoprotective effect of
MSC treatment. It was soon demonstrated that administra-
tion of media conditioned by MSCs was as effective as the
treatment with MSCs themselves in a number of animal
models of disease.21,34,44,102–104 Trophic factors and cytokines
had been detected by proteomic analysis of media condi-
tioned by MSCs, including VEGF, SDF-1, FGF, TGFβ, and IL-1ra,
which appeared to be strong candidates for the promotion of
angiogenesis, and cytoprotection against ischemic-hypoxic
injury and tissue inﬂammation. None of these moieties,
administered individually or in combination, were able to
recapitulate the robust cytoprotective effect observed with
MSCs or MSC-conditioned media treatment.45,105–110 This is
not surprising as the disease precipitated by the tissue
injury is the result of dysfunction of complex multifactorial
pathways. [Delivery of the active moieties of the MSC
secretome to the right tissue compartment in a stable and
bioavailable package is probably the key parameter of
efﬁcacy.]Exosomes are a subset of the heterogeneous population of
extracellular membrane-bound vesicles (EVs) produced by
most, if not all, cell types, including MSCs, and they are also
found in physiological ﬂuids such as urine, plasma, cere-
brospinal ﬂuid, human milk, and exudates (reviewed in Ref.
111). They range in size from 30 to 150 nm in diameter, with
a density of 1.13–1.19 g/mL as determined through ultra-
centrifugation on sucrose cushions or density gradients.112
Their biogenesis involves the endocytic pathway, where
they are generated and stored within multivesicular bodies
(MVBs) prior to their release into the environment through
fusion of the MVB with the cell membrane.46,113 In terms of
their biogenesis and relatively uniform size, exosomes are
quite distinct from other types of EVs, such as those shed
directly from the plasma membrane by budding (often
called ectosomes) and ranging in size from 50 to 1000 nm,
and the much larger and heterogeneous population of
apoptotic blebs (50–5000 nm) that are generated by disinte-
grating cells. As they are formed through the internal
budding of the MVB membrane, exosomes can incorporate
recycled cell membrane proteins, newly synthesized pro-
teins directly from the Golgi and cytoplasmic moieties,
functional mRNAs, miRNAs, and other types of nucleic
acids.
Secreted exosomes can deliver their cargo to target cells,
possibly guided by cell surface receptors such as tetraspanins
and modify the target’s gene expression, signaling, and
overall function. In the immune system, immature dendritic
cells transfer MHC peptide molecules through exosomes to
other dendritic cells to activate the immune response.114
Exosomes from a variety of sources have been reported to
be engulfed by target cells, including macrophages, endothe-
lial cells, or tumor cells,115–117 and the exosomal cargos have
been postulated to represent a vector of genetic exchange and
communication between cells.118
Exosomes were originally described during reticulocyte
maturation to mediate the selective externalization and
removal of the transferrin receptor.119–121 Although the orig-
inal and still major function of the endocytic pathway is a
route to degrade in the lysosome, or to excrete and dispose of
unwanted cellular components, it appears that, through
evolution, components of the mechanism have assumed
additional functions. Such functions may be deleterious, such
as the hijacking of the system by retroviruses for their
biogenesis,122–124 or beneﬁcial, such as the development of a
new level of intracellular signaling by the generation of the
“signalosome,” an exosome harboring speciﬁc functional
cargo that targets other cells (Fig.).
Lung studies with exosomes
In proteomic analysis of the MSC secretome, our group
identiﬁed many immunomodulators and matrix components,
as well as proteins commonly associated with extracellular
vesicles derived from different cell types. Many of these,
including CD63, CD81, moesin, Alix, TSG101, and HSP70, are
enriched in exosomes. The effect of exosomes in vitro has
mostly been focused on their interaction with the immune
system, including dendritic cell maturation, and Treg and B
cell responses.111,125,126 Exosomes isolated from cardiac
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(I/R) injury when injected into the myocardium.103 Exosomes
derived from dendritic cells modulate immune responses and
inhibit rejection from heart transplantation.127 Lee et al.128
demonstrated that exosomes mediate the cytoprotective
effect of bone marrow MSCs in hypoxia-induced pulmonary
hypertension. In this model, administration of MSC-derived
exosomes, identiﬁed through widely accepted exosomal
markers and visualized by electron microscopy, protected
against the elevation of right ventricular systolic pressure
and the development of right ventricular hypertrophy after 3
weeks of hypoxic exposure, while microvesicle-depleted CM
had no effect. Exosomal treatment was also able to abrogate
early hypoxic macrophage inﬂux and downregulate hypoxia-
activated inﬂammatory pathways, thus mediating the anti-
inﬂammatory properties of MSCs. Researchers have isolated
and characterized exosomes from MSCs originating in almost
all sources including from human embryonic stem cells, and
the “MSC exosome” has been proposed as the alternative
therapeutic vehicle for MSCs in many disease models.129–132
Such models of disease include a myocardial injury/reperfu-
sion model in which MSC exosomes decreased infarct size
and ameliorated reperfusion injury133; a cisplatin-induced
acute kidney injury model in the rat where adipose tissue
MSC exosomes ameliorated oxidative stress and cell
apoptosis, promoting cell proliferation in vivo and
in vitro46,134; an acute kidney injury model where MSC
exosomes activated a proliferative program in tubular
cells135; and an airway inﬂammation asthma model where
MSC exosomes suppressed Th2/Th17-mediated allergic air-
way inﬂammation.52
Exosomes released by MSCs may activate kinase pathways
that are critical for ischemic preconditioning by increasing
extracellular ATP levels and decreasing oxidative stress and
inﬂammation.136–138 In a mouse model of hindlimb ischemia,
microvesicles from endothelial progenitor cells improved
neovascularization139 by the transfer of miRNA or mRNA.140
The protection was lost with RNAse treatment or depletion of
miR-126 and miR-296. The same mechanism is thought to
protect the kidney from I/R through the miRNA-dependent
reprogramming of renal resident cells imparted by the deliv-
ery of microvesicles released by EPCs or MSCs.141,142 Mouse
embryonic stem cell–derived exosomes were shown to
enhance cardiac progenitor cell (CPC) function and to pro-
mote cardiac regeneration in a murine model of myocardial
infarction.143 Enrichment of miR-294 in these exosomes was
thought to be responsible for the enhanced CPC survival and
proliferation.
Brain studies with exosomes
In the rat model of neonatal HIE, early reports suggested that
CM of adipose-derived stem cells, delivered through the
jugular vein, improved functional tests 2 months after the
injury and signiﬁcantly protected against hippocampal and
cortical volume loss,104 although the exact therapeutic moi-
ety was not identiﬁed. More recently, in adult animal models
of brain injury, it is reported that the beneﬁcial effects of MSC
treatment resides with secreted exosomes/extracellularvesicles (EVs). The effect of treatment with MSC-derived EVs
was assessed in a rat model of traumatic brain injury. The
treatment involved a single administration through the tail
vein of a preparation of EVs derived from rat BM-MSCs. The
treated animals showed signiﬁcant improvement in spatial
learning and sensorimotor functional recovery assessed up to
34 days posttreatment. The authors observed a signiﬁcant
increase in the number of newly generated endothelial cells
in the lesion boundary zone and dentate gyrus, an increase in
the number of newly formed immature and mature neurons
in the dentate gyrus, and a decrease in neuroinﬂammation,
leading them to suggest that the protective effect of MSC
exosomes was through immunomodulation and the promo-
tion of endogenous angiogenesis and neurogenesis.144 In
another study, the effects of treatment by MSCs and MSC-
derived EVs were systematically compared in a mouse stroke
model of focal cerebral ischemia. MSCs were delivered to
mice on day 1 postinjury and EVs on days 1, 3, and 5
postinjury. Improvement in neurological impairment and
long-term neuroprotection, associated with enhanced angio-
neurogenesis, was observed in animals receiving EVs, and the
EV responses, which persisted throughout the observation
period of 28 days, closely resembled responses to MSCs.
Although the EVs did not affect cerebral immune cell inﬁltra-
tion, treatment resulted in attenuation in systemic immuno-
suppression at the earlier postischemia times.145 In
summary, these and several other studies are emerging to
support a key role for exosomes as messengers for intercel-
lular signaling, with active investigation into their potential
use as therapeutic agents.Clinical trials
For recent reviews on stem cell-based therapies in clinical
trials see Refs. 67, 146, and 147.
BPD clinical trials
Clinical trials that use MSCs for the treatment of a diverse
number of diseases are increasing at a rapid pace (http://
clinicaltrials.gov). The ﬁrst clinical application of MSC therapy
for human BPD was a single-center, phase I dose-escalation
feasibility trial by Chang et al.148 Nine preterm infants, born
at 25.3 7 0.9 weeks’ gestational age assessed to be at highest
risk of BPD, were treated with a single intratracheal dose of
allogeneic, human UCB-MSCs at an average of 10.4 7 2.6
postnatal days. The ﬁrst three infants received 10 million
cells/kg IT and since no immediate adverse events were
noted, the second group of patients received a higher dose
of 20 million cells/kg. The infants were monitored closely for
signs of cardiorespiratory compromise around the time of
MSC administration and followed for incidence and severity
of BPD, markers of lung inﬂammation in tracheal aspirates,
infections, and other multisystem complications. The treat-
ments were well tolerated without immediate side effects or
dose-limiting toxicity, thus demonstrating both feasibility
and short-term safety of allogeneic MSC administration in
preterm neonates at the two tested doses. Because this is a
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of MSC treatment in reducing the incidence and severity of
BPD. There was reduction in inﬂammatory markers in the
tracheal aspirates of treated infants, similar to the reported
observations from several preclinical studies. These infants
are currently being followed for long-term adverse outcomes
and assessment of lung and neurologic health.
HIE clinical trial
No clinical trial has thus far been reported on the use of MSCs
in neonatal brain injury. There is one report to date of
autologous UCB transplantation tested in a phase I trial of
23 infants with HIE that met criteria and received concurrent
therapeutic hypothermia.149 In this open-label study of non-
cryopreserved autologous volume- and red blood cell-reduced
UCB cells, up to 4 doses of 10–50 million cells per dose were
found to be both feasible and well tolerated. Collection of UCB
was successful even with small volumes of cord blood (range:
3–178 mL) to achieve the goal dose for each infusion. No
signiﬁcant adverse reactions, cardiorespiratory compromise,
or infections occurred as a result of the transfusions. Long-
term outcomes are awaited from this trial and the anticipated
phase II trial for both BPD and HIE.Conclusions and perspectives
It is clear that stem cell–based therapies represent the next
breakthrough for diseases of the newborn where endogenous
progenitor cells may be compromised from perinatal insults
and thus contribute to the arrest in normal lung and neuronal
growth underlying BPD, PVL, HIE, and other diseases of the
developing neonate. MSCs are widely used in clinical trials on
adults and were approved in Canada for the treatment of
graft-vs-host disease in children. Their isolation and produc-
tion are relatively simple, and, unlike EPCs/ECFCs, their lack
of immunogenicity makes MSCs an ideal stem cell candidate
to be tested for the treatment of BPD and brain injury.
However, unlike the adult population, additional precautions
and long-term adverse consequences need to be considered
for the immunocompromised, developing preterm infant.
MSCs have the theoretical potential to enhance tumor growth
or lead to malignant transformation, and this concern may be
of particular signiﬁcance in preterm infants due to their
reduced immune surveillance. It is thus critical that all
infants who receive MSCs or other stem cells be monitored
for several years for the theoretical risk of tumor formation. It
is encouraging that a meta-analysis of MSC clinical trials
from over 1000 patients showed no incidence of increased
tumor risk up to 60 months post-treatment.150 Administra-
tion of autologous stem cells obviates any concerns related to
immunogenicity; however, stem cells derived from asphyxi-
ated infants add another level of concern regarding subopti-
mal efﬁcacy. The better identiﬁcation of cell populations in
UCB that confer therapeutic effect and the optimization of
their isolation and delivery, in addition to determining the
optimal dose response and number of doses to achieve
efﬁcacy without signiﬁcant side effects, are unresolved issues.Further work is required to determine the appropriate time
window for stem cell administration in order to maximize
beneﬁt while minimizing risk as well as to identify the best
route and cell source or combination of stem cells to achieve
maximal efﬁcacy. Importantly, biomarkers of efﬁcacy need to
be developed and applied, including the use of imaging modal-
ities and epigenetic and bioinformatic approaches to monitor
therapeutic response and/or side effects.
Although each of these issues requires continued inves-
tigation, at the present time there is a pressing need to
develop novel therapeutic modalities for these as yet incura-
ble diseases that pose a huge burden to the patient, family,
and society. Using the cancer ﬁeld as a model, stem cell or
cell-based transplantation should be widely investigated in
well-designed, collaborative, multicenter clinical trials that
have the power to demonstrate efﬁcacy. In addition to MSCs
or other stem cells, cell-free therapies obviating the theoret-
ical tumorigenic potential of cell transplantation are on the
horizon, including MSC-released extracellular vesicles/exo-
somes. As described above, these critical vectors of MSC
action have the potential to deliver diverse signals, including
proteins, lipids, and nucleic acid material such as mRNA or
noncoding RNA, to the recipient cells and to alter signaling
pathways to restore tissue function. Exosomes in peripheral
blood likely reﬂect the state of the organ of exosomal origin
and thus serve as biomarkers of disease and as prognostic
indicators of response to treatment or progression of disease.
Exosomes from stem cells, such as MSCs, hold signiﬁcant
potential as therapeutic vehicles of epigenetic immunomo-
dulatory signals to treat cardiovascular, pulmonary, renal,
and neurologic injuries. The results from preclinical models
are very promising, but a number of questions remain: is the
production of therapeutic microvesicles a property of all
MSCs, independent of their tissue of origin? This is important
for future large-scale production and clinical translation,
since adipose MSCs, umbilical cord blood, or Wharton’s jelly
MSCs can be obtained much easier than those from bone
marrow. How do the MSC differentiation potential and
passage in culture relate to microvesicle production? This
reﬂects the hurdles associated with MSC characterization and
phenotypic markers. Further critical issues will be the devel-
opment of a “potency assay” and deﬁning the effective
therapeutic dose of MSC exosomes/microvesicles in the
patient as well as the need for large-scale MSC cultures,
which should be readily produced in bioreactors. In addition,
we know very little about the microvesicle mechanism of
action. What is the active cargo they contain and to what
target cell in the injured lung or brain do they deliver it?
Although the predominant effect appears to be immuno-
modulation, the pathways involved are not deﬁned. Further-
more, the fact that a single dose of microvesicles has long-
lasting effects suggests epigenetic regulation of critical sig-
naling pathways of immune function and organ homeostasis.
Clearly, more work is required to better characterize the
biology of MSC-released vesicles/exosomes, and the molec-
ular and epigenetic mechanisms of their action on inﬂam-
matory pathways of injury and repair that underlie lung
diseases such as BPD and the neurologic injuries affecting
newborns such as PVL and HIE.
S E M I N A R S I N P E R I N A T O L O G Y 4 0 ( 2 0 1 6 ) 1 3 8 – 1 5 1 147r e f e r e n c e s
1. Stoll BJ, Hansen NI, Bell EF, et al. Trends in care practices,
morbidity, and mortality of extremely preterm neonates,
1993–2012. J Am Med Assoc. 2015;314(10):1039–1051.
2. Northway WH Jr, Rosan RC, Porter DY. Pulmonary
disease following respirator therapy of hyaline-membrane
disease. Bronchopulmonary dysplasia. N Engl J Med. 1967;
276(7):357–368.
3. Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery
hypertension in formerly premature infants with broncho-
pulmonary dysplasia: clinical features and outcomes in the
surfactant era. Pediatrics. 2007;120(6):1260–1269.
4. del Cerro MJ, Sabate Rotes A, Carton A, et al. Pulmonary
hypertension in bronchopulmonary dysplasia: clinical ﬁnd-
ings, cardiovascular anomalies and outcomes. Pediatr Pulmo-
nol. 2014;49(1):49–59.
5. Bassler D, Plavka R, Shinwell ES, et al. Early inhaled bude-
sonide for the prevention of bronchopulmonary dysplasia. N
Engl J Med. 2015;373(16):1497–1506.
6. Kurinczuk JJ, White-Koning M, Badawi N. Epidemiology of
neonatal encephalopathy and hypoxic-ischaemic encephal-
opathy. Early Hum Dev. 2010;86(6):329–338.
7. Shankaran S, Laptook AR, Ehrenkranz RA, et al. Whole-body
hypothermia for neonates with hypoxic-ischemic encephal-
opathy. N Engl J Med. 2005;353(15):1574–1584.
8. Baker CD, Balasubramaniam V, Mourani PM, et al. Cord blood
angiogenic progenitor cells are decreased in bronchopulmo-
nary dysplasia. Eur Respir J. 2012;40(6):1516–1522.
9. Borghesi A, Massa M, Campanelli R, et al. Circulating endo-
thelial progenitor cells in preterm infants with bronchopul-
monary dysplasia. Am J Respir Crit Care Med. 2009;180(6):
540–546.
10. Popova AP, Bozyk PD, Bentley JK, et al. Isolation of tracheal
aspirate mesenchymal stromal cells predicts bronchopul-
monary dysplasia. Pediatrics. 2010;126(5):e1127–e1133.
11. Bozyk PD, Popova AP, Bentley JK, et al. Mesenchymal stromal
cells from neonatal tracheal aspirates demonstrate a pattern
of lung-speciﬁc gene expression. Stem Cells Dev. 2011;20(11):
1995–2007.
12. Khwaja O, Volpe JJ. Pathogenesis of cerebral white matter
injury of prematurity. Arch Dis Child Fetal Neonatal Ed. 2008;
93(2):F153–F161.
13. Romanov YA, Darevskaya AN, Merzlikina NV, Buravkova LB.
Mesenchymal stem cells from human bone marrow
and adipose tissue: isolation, characterization, and
differentiation potentialities. Bull Exp Biol Med. 2005;140(1):
138–143.
14. Romanov YA, Svintsitskaya VA, Smirnov VN. Searching for
alternative sources of postnatal human mesenchymal stem
cells: candidate msc-like cells from umbilical cord. Stem Cells.
2003;21(1):105–110.
15. Secco M, Zucconi E, Vieira NM, et al. Multipotent stem cells
from umbilical cord: cord is richer than blood!. Stem Cells.
2008;26(1):146–150.
16. Musina RA, Bekchanova ES, Sukhikh GT. Comparison of
mesenchymal stem cells obtained from different human
tissues. Bull Exp Biol Med. 2005;139(4):504–509.
17. Peng L, Jia Z, Yin X, et al. Comparative analysis of mesen-
chymal stem cells from bone marrow, cartilage, and adipose
tissue. Stem Cells Dev. 2008;17(4):761–773.
18. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for
deﬁning multipotent mesenchymal stromal cells. The inter-
national society for cellular therapy position statement.
Cytotherapy. 2006;8(4):315–317.
19. Weiss DJ, Chambers D, Giangreco A, et al. An ofﬁcial
american thoracic society workshop report: stem cells andcell therapies in lung biology and diseases. Ann Am Thorac
Soc. 2015;12(4):S79–S97.
20. Jarvinen L, Badri L, Wettlaufer S, et al. Lung resident
mesenchymal stem cells isolated from human lung allog-
rafts inhibit T cell proliferation via a soluble mediator. J
Immunol. 2008;181(6):4389–4396.
21. van Koppen A, Joles JA, van Balkom BW, et al. Human
embryonic mesenchymal stem cell-derived conditioned
medium rescues kidney function in rats with established
chronic kidney disease. PLoS One. 2012;7(6):e38746.
22. Schreml S, Babilas P, Fruth S, et al. Harvesting human
adipose tissue-derived adult stem cells: resection versus
liposuction. Cytotherapy. 2009;11(7):947–957.
23. de Sa Silva F, Almeida PN, Rettore JV, et al. Toward person-
alized cell therapies by using stem cells: seven relevant
topics for safety and success in stem cell therapy. J Biomed
Biotechnol. 2012;2012:758102.
24. Le Blanc K, Ringden O. Immunobiology of human mesenchy-
mal stem cells and future use in hematopoietic stem cell
transplantation. Biol Blood Marrow Transplant. 2005;11(5):321–334.
25. Beyth S, Borovsky Z, Mevorach D, et al. Human mesenchymal
stem cells alter antigen-presenting cell maturation and
induce T-cell unresponsiveness. Blood. 2005;105(5):2214–2219.
26. Duffy MM, Ritter T, Ceredig R, Grifﬁn MD. Mesenchymal stem
cell effects on T-cell effector pathways. Stem Cell Res Ther.
2011;2(4):34.
27. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Mor-
etta L. Mesenchymal stem cell-natural killer cell interac-
tions: evidence that activated nk cells are capable of killing
mscs, whereas mscs can inhibit il-2-induced nk-cell prolif-
eration. Blood. 2006;107(4):1484–1490.
28. Jansen BJ, Gilissen C, Roelofs H, et al. Functional differences
between mesenchymal stem cell populations are reﬂected
by their transcriptome. Stem Cells Dev. 2010;19(4):481–490.
29. Kuang PP, Lucey E, Rishikof DC, Humphries DE, Bronsnick D,
Goldstein RH. Engraftment of neonatal lung ﬁbroblasts into
the normal and elastase-injured lung. Am J Respir Cell Mol
Biol. 2005;33(4):371–377.
30. Tsai MS, Hwang SM, Chen KD, et al. Functional network
analysis of the transcriptomes of mesenchymal stem cells
derived from amniotic ﬂuid, amniotic membrane, cord
blood, and bone marrow. Stem Cells. 2007;25(10):2511–2523.
31. Binato R, de Souza Fernandez T, Lazzarotto-Silva C, et al.
Stability of human mesenchymal stem cells during in vitro
culture: considerations for cell therapy. Cell Prolif. 2013;46(1):
10–22.
32. Foudah D, Redaelli S, Donzelli E, et al. Monitoring the
genomic stability of in vitro cultured rat bone-marrow-
derived mesenchymal stem cells. Chromosome Res. 2009;17(8):
1025–1039.
33. Zhou YF, Bosch-Marce M, Okuyama H, et al. Spontaneous
transformation of cultured mouse bone marrow-derived
stromal cells. Cancer Res. 2006;66(22):10849–10854.
34. Aslam M, Baveja R, Liang OD, et al. Bone marrow stromal
cells attenuate lung injury in a murine model of neonatal
chronic lung disease. Am J Respir Crit Care Med. 2009;180
(11):1122–1130.
35. Chang YS, Choi SJ, Sung DK, et al. Intratracheal transplanta-
tion of human umbilical cord blood-derived mesenchymal
stem cells dose-dependently attenuates hyperoxia-induced
lung injury in neonatal rats. Cell Transplant. 2011;20(11-12):
1843–1854.
36. van Haaften T, Byrne R, Bonnet S, et al. Airway delivery of
mesenchymal stem cells prevents arrested alveolar growth
in neonatal lung injury in rats. Am J Respir Crit Care Med.
2009;180(11):1131–1142.
37. Sutsko RP, Young KC, Ribeiro A, et al. Long-term reparative
effects of mesenchymal stem cell therapy following
S E M I N A R S I N P E R I N A T O L O G Y 4 0 ( 2 0 1 6 ) 1 3 8 – 1 5 1148neonatal hyperoxia-induced lung injury. Pediatr Res. 2013;
73(1):46–53.
38. Zhang X, Wang H, Shi Y, et al. Role of bone marrow-derived
mesenchymal stem cells in the prevention of hyperoxia-
induced lung injury in newborn mice. Cell Biol Int. 2012;
36(6):589–594.
39. Chang YS, Oh W, Choi SJ, et al. Human umbilical cord blood-
derived mesenchymal stem cells attenuate hyperoxia-
induced lung injury in neonatal rats. Cell Transplant.
2009;18(8):869–886.
40. Pierro M, Ionescu L, Montemurro T, et al. Short-term, long-
term and paracrine effect of human umbilical cord-derived
stem cells in lung injury prevention and repair in exper-
imental bronchopulmonary dysplasia. Thorax. 2013;68(5):
475–484.
41. Chang YS, Choi SJ, Ahn SY, et al. Timing of umbilical cord
blood derived mesenchymal stem cells transplantation
determines therapeutic efﬁcacy in the neonatal hyperoxic
lung injury. PLoS One. 2013;8(1):e52419.
42. Hansmann G, Fernandez-Gonzalez A, Aslam M, et al. Mes-
enchymal stem cell-mediated reversal of bronchopulmonary
dysplasia and associated pulmonary hypertension. Pulm Circ.
2012;2(2):170–181.
43. Islam MN, Das SR, Emin MT, et al. Mitochondrial transfer
from bone-marrow-derived stromal cells to pulmonary
alveoli protects against acute lung injury. Nat Med. 2012;
18(5):759–765.
44. Timmers L, Lim SK, Arslan F, et al. Reduction of myocardial
infarct size by human mesenchymal stem cell conditioned
medium. Stem Cell Res. 2007;1(2):129–137.
45. Kinnaird T, Stabile E, Burnett MS, Epstein SE. Bone-marrow-
derived cells for enhancing collateral development: mecha-
nisms, animal data, and initial clinical experiences. Circ Res.
2004;95(4):354–363.
46. Dorronsoro A, Robbins PD. Regenerating the injured kidney
with human umbilical cord mesenchymal stem cell-derived
exosomes. Stem Cell Res Ther. 2013;4(2):39.
47. Tetta C, Bruno S, Fonsato V, Deregibus MC, Camussi G. The
role of microvesicles in tissue repair. Organogenesis. 2011;
7(2):105–115.
48. Pisitkun T, Shen RF, Knepper MA. Identiﬁcation and proteo-
mic proﬁling of exosomes in human urine. Proc Natl Acad Sci
U S A. 2004;101(36):13368–13373.
49. Pant S, Hilton H, Burczynski ME. The multifaceted exosome:
biogenesis, role in normal and aberrant cellular function,
and frontiers for pharmacological and biomarker opportu-
nities. Biochem Pharmacol. 2012;83(11):1484–1494.
50. Rana S, Zoller M. Exosome target cell selection and the
importance of exosomal tetraspanins: a hypothesis. Biochem
Soc Trans. 2011;39(2):559–562.
51. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ.
Delivery of sirna to the mouse brain by systemic injection of
targeted exosomes. Nat Biotechnol. 2011;29(4):341–345.
52. Cruz FF, Borg ZD, Goodwin M, et al. Systemic administration
of human bone marrow-derived mesenchymal stromal cell
extracellular vesicles ameliorates aspergillus hyphal extract-
induced allergic airway inﬂammation in immunocompetent
mice. Stem Cells Transl Med. 2015;4(11):1302–1316.
53. Sung DK, Chang YS, Ahn SY, et al. Optimal route for human
umbilical cord blood-derived mesenchymal stem cell trans-
plantation to protect against neonatal hyperoxic lung injury:
gene expression proﬁles and histopathology. PLoS One.
2015;10(8):e0135574.
54. Tibboel J, Keijzer R, Reiss I, de Jongste JC, Post M. Intravenous
and intratracheal mesenchymal stromal cell injection in a
mouse model of pulmonary emphysema. COPD. 2014;11(3):
310–318.55. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA,
Maniscalco WM. Disrupted pulmonary vasculature and
decreased vascular endothelial growth factor, Flt-1, and
TIE-2 in human infants dying with bronchopulmonary
dysplasia. Am J Respir Crit Care Med. 2001;164(10 Pt 1):
1971–1980.
56. Thebaud B, Ladha F, Michelakis ED, et al. Vascular endothelial
growth factor gene therapy increases survival, promotes lung
angiogenesis, and prevents alveolar damage in hyperoxia-
induced lung injury: evidence that angiogenesis participates
in alveolarization. Circulation. 2005;112(16):2477–2486.
57. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative
progenitor endothelial cells for angiogenesis. Science.
1997;275(5302):964–967.
58. Ingram DA, Mead LE, Tanaka H, et al. Identiﬁcation of a
novel hierarchy of endothelial progenitor cells using human
peripheral and umbilical cord blood. Blood. 2004;104(9):
2752–2760.
59. Yoder MC, Mead LE, Prater D, et al. Redeﬁning endothelial
progenitor cells via clonal analysis and hematopoietic stem/
progenitor cell principals. Blood. 2007;109(5):1801–1809.
60. Balasubramaniam V, Ryan SL, Seedorf GJ, et al. Bone
marrow-derived angiogenic cells restore lung alveolar and
vascular structure after neonatal hyperoxia in infant mice.
Am J Physiol Lung Cell Mol Physiol. 2010;298(3):L315–L323.
61. Baker CD, Seedorf GJ, Wisniewski BL, et al. Endothelial
colony-forming cell conditioned media promote angiogene-
sis in vitro and prevent pulmonary hypertension in exper-
imental bronchopulmonary dysplasia. Am J Physiol Lung Cell
Mol Physiol. 2013;305(1):L73–L81.
62. Alphonse RS, Vadivel A, Fung M, et al. Existence, functional
impairment, and lung repair potential of endothelial colony-
forming cells in oxygen-induced arrested alveolar growth.
Circulation. 2014;129(21):2144–2157.
63. Ilancheran S, Michalska A, Peh G, Wallace EM, Pera M,
Manuelpillai U. Stem cells derived from human fetal mem-
branes display multilineage differentiation potential. Biol
Reprod. 2007;77(3):577–588.
64. Moodley Y, Ilancheran S, Samuel C, et al. Human amnion
epithelial cell transplantation abrogates lung ﬁbrosis and
augments repair. Am J Respir Crit Care Med. 2010;182(5):643–651.
65. Vosdoganes P, Hodges RJ, Lim R, et al. Human amnion
epithelial cells as a treatment for inﬂammation-induced
fetal lung injury in sheep. Am J Obstet Gynecol. 2011;205(2):
156.e126–156.e133.
66. Hodges RJ, Jenkin G, Hooper SB, et al. Human amnion
epithelial cells reduce ventilation-induced preterm lung
injury in fetal sheep. Am J Obstet Gynecol. 2012;206(5):
448.e8–448.e15.
67. Pawelec K, Gladysz D, Demkow U, Boruczkowski D. Stem cell
experiments moves into clinic: new hope for children with
bronchopulmonary dysplasia. Adv Exp Med Biol. 2015;839:
47–53.
68. Sdrimas K, Kourembanas S. Msc microvesicles for the treat-
ment of lung disease: a new paradigm for cell-free therapy.
Antioxid Redox Signal. 2014;21(13):1905–1915.
69. Weiss DJ. Stem cells, cell therapies, and bioengineering in
lung biology and diseases. Comprehensive review of the
recent literature 2010–2012. Ann Am Thorac Soc. 2013;10(5):
S45–S97.
70. Wansleeben C, Barkauskas CE, Rock JR, Hogan BL. Stem cells
of the adult lung: their development and role in homeo-
stasis, regeneration, and disease. Wiley Interdiscip Rev Dev
Biol. 2013;2(1):131–148.
71. Borghesi A, Cova C, Gazzolo D, Stronati M. Stem cell therapy
for neonatal diseases associated with preterm birth. J Clin
Neonatol. 2013;2(1):1–7.
S E M I N A R S I N P E R I N A T O L O G Y 4 0 ( 2 0 1 6 ) 1 3 8 – 1 5 1 14972. Fung ME, Thebaud B. Stem cell-based therapy for neonatal
lung disease: it is in the juice. Pediatr Res. 2014;75(1-1):2–7.
73. Foronjy RF, Majka SM. The potential for resident lung
mesenchymal stem cells to promote functional tissue regen-
eration: understanding microenvironmental cues. Cells.
2012;1(4):874.
74. Jun D, Garat C, West J, et al. The pathology of bleomycin-
induced ﬁbrosis is associated with loss of resident lung
mesenchymal stem cells that regulate effector T-cell prolif-
eration. Stem Cells. 2011;29(4):725–735.
75. Chow K, Fessel JP, Kaoriihida S, et al. Dysfunctional resident
lung mesenchymal stem cells contribute to pulmonary
microvascular remodeling. Pulm Circ. 2013;3(1):31–49.
76. Popova AP, Bentley JK, Anyanwu AC, et al. Glycogen syn-
thase kinase-3 beta/beta-catenin signaling regulates neo-
natal lung mesenchymal stromal cell myoﬁbroblastic
differentiation. Am J Physiol Lung Cell Mol Physiol. 2012;303(5):
L439–L448.
77. Tropea KA, Leder E, Aslam M, et al. Bronchioalveolar stem
cells increase after mesenchymal stromal cell treatment in a
mouse model of bronchopulmonary dysplasia. Am J Physiol
Lung Cell Mol Physiol. 2012;302(9):L829–L837.
78. Titomanlio L, Kavelaars A, Dalous J, et al. Stem cell therapy
for neonatal brain injury: perspectives and challenges. Ann
Neurol. 2011;70(5):698–712.
79. Verina T, Fatemi A, Johnston MV, Comi AM. Pluripotent
possibilities: human umbilical cord blood cell treatment
after neonatal brain injury. Pediatr Neurol. 2013;48(5):346–354.
80. Chicha L, Smith T, Guzman R. Stem cells for brain
repair in neonatal hypoxia-ischemia. Childs Nerv Syst. 2014;
30(1):37–46.
81. Carroll J. Human cord blood for the hypoxic-ischemic neo-
nate. Pediatr Res. 2012;71(4 Pt 2):459–463.
82. Gonzales-Portillo GS, Reyes S, Aguirre D, Pabon MM, Borlon-
gan CV. Stem cell therapy for neonatal hypoxic-ischemic
encephalopathy. Front Neurol. 2014;5:147.
83. Fleiss B, Guillot PV, Titomanlio L, Baud O, Hagberg H,
Gressens P. Stem cell therapy for neonatal brain injury. Clin
Perinatol. 2014;41(1):133–148.
84. Bennet L, Tan S, Van den Heuij L, et al. Cell therapy for
neonatal hypoxia-ischemia and cerebral palsy. Ann Neurol.
2012;71(5):589–600.
85. van Velthoven CT, Kavelaars A, Heijnen CJ. Mesenchymal
stem cells as a treatment for neonatal ischemic brain
damage. Pediatr Res. 2012;71(4 pt 2):474–481.
86. Hegyi B, Kornyei Z, Ferenczi S, et al. Regulation of mouse
microglia activation and effector functions by bone marrow-
derived mesenchymal stem cells. Stem Cells Dev. 2014;23(21):
2600–2612.
87. Kim ES, Ahn SY, Im GH, et al. Human umbilical cord blood-
derived mesenchymal stem cell transplantation attenuates
severe brain injury by permanent middle cerebral artery
occlusion in newborn rats. Pediatr Res. 2012;72(3):277–284.
88. Chen A, Siow B, Blamire AM, Lako M, Clowry GJ. Trans-
plantation of magnetically labeled mesenchymal stem cells
in a model of perinatal brain injury. Stem Cell Res. 2010;5(3):
255–266.
89. Lee JA, Kim BI, Jo CH, et al. Mesenchymal stem-cell trans-
plantation for hypoxic-ischemic brain injury in neonatal rat
model. Pediatr Res. 2010;67(1):42–46.
90. Ohshima M, Taguchi A, Tsuda H, et al. Intraperitoneal and
intravenous deliveries are not comparable in terms of drug
efﬁcacy and cell distribution in neonatal mice with hypoxia-
ischemia. Brain Dev. 2015;37(4):376–386.
91. Donega V, Nijboer CH, van Velthoven CT, et al. Assessment
of long-term safety and efﬁcacy of intranasal mesenchymal
stem cell treatment for neonatal brain injury in the mouse.
Pediatr Res. 2015;78(5):520–526.92. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ.
Mesenchymal stem cell treatment after neonatal hypoxic-
ischemic brain injury improves behavioral outcome and
induces neuronal and oligodendrocyte regeneration. Brain
Behav Immun. 2010;24(3):387–393.
93. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ. Nasal
administration of stem cells: a promising novel route to treat
neonatal ischemic brain damage. Pediatr Res. 2010;68(5):
419–422.
94. van Velthoven CT, van de Looij Y, Kavelaars A, et al.
Mesenchymal stem cells restore cortical rewiring after neo-
natal ischemia in mice. Ann Neurol. 2012;71(6):785–796.
95. Donega V, van Velthoven CT, Nijboer CH, et al. Intranasal
mesenchymal stem cell treatment for neonatal brain dam-
age: long-term cognitive and sensorimotor improvement.
PLoS One. 2013;8(1):e51253.
96. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ.
Repeated mesenchymal stem cell treatment after neonatal
hypoxia-ischemia has distinct effects on formation and
maturation of new neurons and oligodendrocytes
leading to restoration of damage, corticospinal motor tract
activity, and sensorimotor function. J Neurosci. 2010;30(28):
9603–9611.
97. van Velthoven CT, Kavelaars A, van Bel F, Heijnen CJ.
Mesenchymal stem cell transplantation changes the gene
expression proﬁle of the neonatal ischemic brain. Brain
Behav Immun. 2011;25(7):1342–1348.
98. Donega V, Nijboer CH, Braccioli L, et al. Intranasal admin-
istration of human msc for ischemic brain injury in the
mouse: in vitro and in vivo neuroregenerative functions.
PLoS One. 2014;9(11):e112339.
99. van Velthoven CT, Braccioli L, Willemen HL, Kavelaars A,
Heijnen CJ. Therapeutic potential of genetically modiﬁed
mesenchymal stem cells after neonatal hypoxic-ischemic
brain damage. Mol Ther. 2014;22(3):645–654.
100. van Velthoven CT, Sheldon RA, Kavelaars A, et al. Mesen-
chymal stem cell transplantation attenuates brain injury
after neonatal stroke. Stroke. 2013;44(5):1426–1432.
101. Park WS, Sung SI, Ahn SY, et al. Hypothermia augments
neuroprotective activity of mesenchymal stem cells for
neonatal hypoxic-ischemic encephalopathy. PLoS One.
2015;10(3):e0120893.
102. Abman SH, Matthay MA. Mesenchymal stem cells for the
prevention of bronchopulmonary dysplasia: delivering the
secretome. Am J Respir Crit Care Med. 2009;180(11):1039–1041.
103. Chen L, Wang Y, Pan Y, et al. Cardiac progenitor-derived
exosomes protect ischemic myocardium from acute ische-
mia/reperfusion injury. Biochem Biophys Res Commun.
2013;431(3):566–571.
104. Wei X, Du Z, Zhao L, et al. Ifats collection: the conditioned
media of adipose stromal cells protect against hypoxia-
ischemia-induced brain damage in neonatal rats. Stem Cells.
2009;27(2):478–488.
105. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C.
Administered mesenchymal stem cells protect against
ischemic acute renal failure through differentiation-
independent mechanisms. Am J Physiol Renal Physiol. 2005;
289(1):F31–F42.
106. Nakagami H, Maeda K, Morishita R, et al. Novel autologous
cell therapy in ischemic limb disease through growth factor
secretion by cultured adipose tissue-derived stromal cells.
Arterioscler Thromb Vasc Biol. 2005;25(12):2542–2547.
107. Van Overstraeten-Schlogel N, Beguin Y, Gothot A. Role of
stromal-derived factor-1 in the hematopoietic-supporting
activity of human mesenchymal stem cells. Eur J Haematol.
2006;76(6):488–493.
108. Ortiz LA, Dutreil M, Fattman C, et al. Interleukin 1 receptor
antagonist mediates the antiinﬂammatory and antiﬁbrotic
S E M I N A R S I N P E R I N A T O L O G Y 4 0 ( 2 0 1 6 ) 1 3 8 – 1 5 1150effect of mesenchymal stem cells during lung injury. Proc
Natl Acad Sci U S A. 2007;104(26):11002–11007.
109. Kupcova Skalnikova H. Proteomic techniques for character-
isation of mesenchymal stem cell secretome. Biochimie.
2013;95(12):2196–2211.
110. Lavoie JR, Rosu-Myles M. Uncovering the secretes of mesen-
chymal stem cells. Biochimie. 2013;95(12):2212–2221.
111. Thery C, Ostrowski M, Segura E. Membrane vesicles as
conveyors of immune responses. Nat Rev Immunol. 2009;9
(8):581–593.
112. Thery C, Amigorena S, Raposo G, Clayton A. Isolation and
characterization of exosomes from cell culture supernatants
and biological ﬂuids. Curr Protoc Cell Biol. 2006;[chapter 3: unit]
3:22.
113. Thery C, Zitvogel L, Amigorena S. Exosomes: composition,
biogenesis and function. Nat Rev Immunol. 2002;2(8):569–579.
114. Segura E, Amigorena S, Thery C. Mature dendritic cells
secrete exosomes with strong ability to induce antigen-
speciﬁc effector immune responses. Blood Cells Mol Dis.
2005;35(2):89–93.
115. Barres C, Blanc L, Bette-Bobillo P, et al. Galectin-5 is bound
onto the surface of rat reticulocyte exosomes and modulates
vesicle uptake by macrophages. Blood. 2010;115(3):696–705.
116. Tian T, Wang Y, Wang H, Zhu Z, Xiao Z. Visualizing of the
cellular uptake and intracellular trafﬁcking of exosomes by
live-cell microscopy. J Cell Biochem. 2010;111(2):488–496.
117. Skog J, Wurdinger T, van Rijn S, et al. Glioblastoma micro-
vesicles transport rna and proteins that promote tumour
growth and provide diagnostic biomarkers. Nat Cell Biol.
2008;10(12):1470–1476.
118. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall
JO. Exosome-mediated transfer of mrnas and micrornas is a
novel mechanism of genetic exchange between cells. Nat Cell
Biol. 2007;9(6):654–659.
119. Trams EG, Lauter CJ, Salem N Jr., Heine U. Exfoliation of
membrane ecto-enzymes in the form of micro-vesicles.
Biochim Biophys Acta. 1981;645(1):63–70.
120. Pan BT, Johnstone RM. Fate of the transferrin receptor
during maturation of sheep reticulocytes in vitro: selective
externalization of the receptor. Cell. 1983;33(3):967–978.
121. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C.
Vesicle formation during reticulocyte maturation. Associa-
tion of plasma membrane activities with released vesicles
(exosomes). J Biol Chem. 1987;262(19):9412–9420.
122. Gould SJ, Booth AM, Hildreth JE. The trojan exosome hypoth-
esis. Proc Natl Acad Sci U S A. 2003;100(19):10592–10597.
123. Kramer B, Pelchen-Matthews A, Deneka M, Garcia E, Piguet V,
Marsh M. Hiv interaction with endosomes in macrophages and
dendritic cells. Blood Cells Mol Dis. 2005;35(2):136–142.
124. Wurdinger T, Gatson NN, Balaj L, Kaur B, Breakeﬁeld XO,
Pegtel DM. Extracellular vesicles and their convergence with
viral pathways. Adv Virol. 2012;2012:767694.
125. Kitazawa Y, Li XK, Xie L, Zhu P, Kimura H, Takahara S. Bone
marrow-derived conventional, but not cloned, mesenchy-
mal stem cells suppress lymphocyte proliferation and pre-
vent graft-versus-host disease in rats. Cell Transplant. 2012;21
(2-3):581–590.
126. Budoni M, Fierabracci A, Luciano R, Petrini S, Di Ciommo V,
Muraca M. The immunosuppressive effect of mesenchymal
stromal cells on b lymphocytes is mediated by membrane
vesicles. Cell Transplant. 2013;22(2):369–379.
127. Peche H, Heslan M, Usal C, Amigorena S, Cuturi MC.
Presentation of donor major histocompatibility complex
antigens by bone marrow dendritic cell-derived exosomes
modulates allograft rejection. Transplantation. 2003;76(10):
1503–1510.
128. Lee C, Mitsialis SA, Aslam M, et al. Exosomes mediate
the cytoprotective action of mesenchymal stromal cells onhypoxia-induced pulmonary hypertension. Circulation. 2012;
126(22):2601–2611.
129. Parekkadan B, van Poll D, Suganuma K, et al. Mesenchymal
stem cell-derived molecules reverse fulminant hepatic fail-
ure. PLoS One. 2007;2(9):e941.
130. Ranganath SH, Levy O, Inamdar MS, Karp JM. Harnessing the
mesenchymal stem cell secretome for the treatment of
cardiovascular disease. Cell Stem Cell. 2012;10(3):244–258.
131. Baglio SR, Pegtel DM, Baldini N. Mesenchymal stem cell
secreted vesicles provide novel opportunities in (stem) cell-
free therapy. Front Physiol. 2012;3:359.
132. Yeo RW, Lai RC, Zhang B, et al. Mesenchymal stem cell: an
efﬁcient mass producer of exosomes for drug delivery. Adv
Drug Deliv Rev. 2013;65(3):336–341.
133. Lai RC, Arslan F, Lee MM, et al. Exosome secreted by msc
reduces myocardial ischemia/reperfusion injury. Stem Cell
Res. 2010;4(3):214–222.
134. Zhou Y, Xu H, Xu W, et al. Exosomes released by human
umbilical cord mesenchymal stem cells protect against
cisplatin-induced renal oxidative stress and apoptosis
in vivo and in vitro. Stem Cell Res Ther. 2013;4(2):34.
135. Bruno S, Grange C, Deregibus MC, et al. Mesenchymal stem
cell-derived microvesicles protect against acute tubular
injury. J Am Soc Nephrol. 2009;20(5):1053–1067.
136. Liu GS, Thornton J, Van Winkle DM, Stanley AW, Olsson RA,
Downey JM. Protection against infarction afforded by pre-
conditioning is mediated by a1 adenosine receptors in rabbit
heart. Circulation. 1991;84(1):350–356.
137. Kitakaze M, Hori M, Takashima S, Sato H, Inoue M, Kamada
T. Ischemic preconditioning increases adenosine release
and 50-nucleotidase activity during myocardial ischemia
and reperfusion in dogs. Implications for myocardial sal-
vage. Circulation. 1993;87(1):208–215.
138. Arslan F, Lai RC, Smeets MB, et al. Mesenchymal stem cell-
derived exosomes increase atp levels, decrease oxidative
stress and activate pi3k/akt pathway to enhance myocardial
viability and prevent adverse remodeling after myocardial
ischemia/reperfusion injury. Stem Cell Res. 2013;10(3):301–312.
139. Ranghino A, Cantaluppi V, Grange C, et al. Endothelial
progenitor cell-derived microvesicles improve neovasculari-
zation in a murine model of hindlimb ischemia. Int J
Immunopathol Pharmacol. 2012;25(1):75–85.
140. Deregibus MC, Cantaluppi V, Calogero R, et al. Endothelial
progenitor cell derived microvesicles activate an angiogenic
program in endothelial cells by a horizontal transfer of
mrna. Blood. 2007;110(7):2440–2448.
141. Gatti S, Bruno S, Deregibus MC, et al. Microvesicles derived
from human adult mesenchymal stem cells protect against
ischaemia-reperfusion-induced acute and chronic kidney
injury. Nephrol Dial Transplant. 2011;26(5):1474–1483.
142. Cantaluppi V, Gatti S, Medica D, et al. Microvesicles
derived from endothelial progenitor cells protect the kidney
from ischemia-reperfusion injury by microrna-dependent
reprogramming of resident renal cells. Kidney Int. 2012;
82(4):412–427.
143. Khan M, Nickoloff E, Abramova T, et al. Embryonic stem cell-
derived exosomes promote endogenous repair mechanisms
and enhance cardiac function following myocardial infarc-
tion. Circ Res. 2015;117(1):52–64.
144. Zhang Y, Chopp M, Meng Y, et al. Effect of exosomes
derived from multipluripotent mesenchymal stromal
cells on functional recovery and neurovascular plasticity in
rats after traumatic brain injury. J Neurosurg. 2015;122(4):
856–867.
145. Doeppner TR, Herz J, Gorgens A, et al. Extracellular vesicles
improve post-stroke neuroregeneration and prevent posti-
schemic immunosuppression. Stem Cells Transl Med. 2015;4
(10):1131–1143.
S E M I N A R S I N P E R I N A T O L O G Y 4 0 ( 2 0 1 6 ) 1 3 8 – 1 5 1 151146. Trounson A, McDonald C. Stem cell therapies in clinical
trials: progress and challenges. Cell Stem Cell. 2015;17(1):11–22.
147. Ahn SY, Chang YS, Park WS. Stem cell therapy for broncho-
pulmonary dysplasia: bench to bedside translation. J Korean
Med Sci. 2015;30(5):509–513.
148. Chang YS, Ahn SY, Yoo HS, et al. Mesenchymal stem cells
for bronchopulmonary dysplasia: phase 1 dose-escalation
clinical trial. J Pediatr. 2014;164(5):966–972.e6.149. Cotten CM, Murtha AP, Goldberg RN, et al. Feasibility
of autologous cord blood cells for infants with hypoxic-
ischemic encephalopathy. J Pediatr. 2014;164(5):973–
979.e1.
150. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy
with mesenchymal stromal cells (safecell): a systematic
review and meta-analysis of clinical trials. PLoS One. 2012;
7(10):e47559.
